Rise and shine, everyone, another busy day is on the way. This is especially true here at the Pharmalot campus, where we are playing catch-up after a series of appointments yesterday that disrupted our usually intense routine. We are now trying to compensate by firing up the coffee kettle and brewing multiple cups of stimulation. Our flavor today is blueberry morning, an old standby, for those who track this sort of thing. Meanwhile, here are some items of interest to help you on your own journey. Hope you conquer the world and, as always, do stay in touch …

Gilead Sciences (GILD) will begin airing television ads for PrEP, its HIV prevention medication, NBC News tells us. Since winning regulatory approval for the $1,000-a-month pill, which is called Truvada, Gilead has leaned on public health agencies to promote the drug, but spent only several hundred thousand dollars per year in direct advertising. The drug maker maintains, however, that it has granted more than $28 million to approximately 120 organizations since 2012 to support their efforts to promote PrEP, but that works out to less than $5 million a year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • While one understands that when Mr Trump speaks, it is news, such …. bombast should not grace the pages of the Pharmalot. May I request our scribe mark this entry for a follow-up notice on 15 JUNE 2018? At that point, we can determine if this was indeed ‘news’ or much more likely ‘FAKE news.’

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy